Printer Friendly

VERTEX LICENSES VX-944 TO AVALON FOR CANCER TREATMENT.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated have entered into a licensing agreement for the development of the investigational agent VX- 944 in oncology indications. Under the terms of the agreement, Avalon will hold exclusive rights to develop and commercialize VX-944 worldwide for the treatment of various cancers. Avalon, a privately held company with a therapeutic focus in cancer, will make up to $73 million in up-front license fees and milestone payments to Vertex based on the successful development and commercialization of VX-944 in oncology. Upon commercialization, Vertex will receive royalties on product sales. Vertex retains certain rights to co-promote VX-944 in U.S. and European markets.

VX-944, a small molecule IMPDH inhibitor discovered by Vertex Pharmaceuticals, has completed a single-dose, Phase I study in healthy volunteers. Recent reports in medical literature and presentations at scientific conferences provide a strong clinical rationale for the development of IMPDH inhibitors generally, and VX-944 specifically, in hematologic malignancies. Results presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2004 indicated that VX-944 inhibited the in vitro proliferation of lymphoid and myeloid cells, the principal cells involved in the most common types of human leukemias. In addition, VX-944 was shown to significantly prolong survival in a model of aggressive mouse leukemia. Based on these results, Avalon plans to initiate a clinical trial with VX-944 in a hematologic cancer indication in the second half of 2005. In addition, Avalon expects to use its chemical genomics platform to evaluate VX-944's potential in the treatment of solid tumors.

"Avalon is pleased to collaborate with Vertex, a proven leader in the discovery and development of small molecule therapeutics," said Kenneth C. Carter, Ph.D., president and Chief Executive Officer of Avalon Pharmaceuticals. "The AvalonRx( drug discovery and analysis engine has enabled us to build a pipeline of novel oncology targets and therapeutic compounds, and this collaboration accelerates our downstream integration toward the development and commercialization of new cancer treatments. Further using our platforms, we will build on Vertex's studies and develop biomarkers for stratification and monitoring for efficacy in patients."

"Based on its unique anti-proliferative mechanism, VX-944 holds strong potential in the treatment of hematologic cancers, as well as other tumor types," said Joshua Boger, Ph.D., Chairman and CEO of Vertex. "This licensing agreement with Avalon places VX-944 in the hands of a committed partner. We expect that Avalon will rapidly advance this compound from early development to clinical proof-of-concept, fulfilling an important strategic objective for the VX-944 program."

About Avalon

Avalon Pharmaceuticals utilizes unique and proprietary forward chemical genomics-based methods to accelerate the discovery of novel targets and drugs. Avalon's unique capabilities in cytogenetics and gene expression analysis allow Avalon to rapidly discover and validate novel oncology targets. For the discovery of small molecules Avalon utilizes a comprehensive systems approach, enabling more informed decisions at earlier stages in the drug discovery process. The AvalonRx( drug discovery platform allows for the rapid identification of lead compounds through an enriched understanding of the mechanism of action within diseased cells, leading to accelerated medicinal chemistry driven lead optimization programs and clinical development. This revolutionary systems approach is applicable across multiple disease areas. In December 2004, Avalon was recognized by Red Herring as one of the top 100 innovator companies. Currently, Avalon is focusing its efforts to produce the next generation of cancer medicines.

For more information, visit http://www.avalonrx.com or call 301/556-9810.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the HIV protease inhibitor, Lexiva(r) with GlaxoSmithKline. For more information, call 617/444-6108.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Apr 1, 2004
Words:644
Previous Article:CELLIANCE ADDS SERUM-FREE HYBRI-CYTE TO CELL CULTURE PORTFOLIO.
Next Article:PROVENGE/AVASTIN IMPACT PSA DOUBLING TIME IN PROSTATE CANCER.
Topics:


Related Articles
Vertex Pharmaceuticals receives United States patent covering assay technology to accelerate drug discovery targeting hepatitis C protease.
Vertex secures hepatitis C license agreement.
Aventis and Vertex discontinue arthritis drug trial.
Aventis and Avalon form oncology collaboration.
VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
Vertex to start Phase II trial for investigational Oral HCV protease inhibitor, FDA grants Fast Track designation.
VERTEX REPORTS 2007 3RD QTR NET LOSS OF $107 MILLION.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters